Target audience: Physicians, PAs, Nurses and Nurse Practitioners
Credit designations available: AMA PRA Category 1 Credit™, AAPA Category 1 CME Credit, Nursing Contact Hour(s)
This roundtable looks at high-potency “kratom” products, how patients are using and the appropriate management strategies, including withdrawal treatment and buprenorphine prescribing. The discussion is structured to encourage interactivity through an informal roundtable conversation. Attendees will have the opportunity to engage directly with the presenters, ask questions, and discuss relevant issues.
At the conclusion of this activity participants should be able to:
- Recognize current trends in 7-OH/MP and other high-potency “kratom” products.
- Distinguish whole-leaf kratom from extracts/isolated alkaloids, their pharmacology, and their risks.
- Assess patients using these products (history, co-use, tox testing, diagnosis).
- Choose appropriate management, including withdrawal treatment and buprenorphine strategies when indicated.
Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
